Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Novo Ventures and Catalys Pacific, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. The company’s lead candidate, dotinurad, is a next-generation URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved. Crystalys is advancing dotinurad in global Phase 3 trials toward regulatory approval and commercial launch.
For more information, visit www.crystalystx.com.